|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...4243444546474849505152...6768» |
- || Biostate (factor VIII/von Willebrand factor) / CSL Behring
Trial completion: Study of Biostate® in Children With Von Willebrand Disease (clinicaltrials.gov) - Nov 11, 2013
P3, N=17, Completed, Sponsor: CSL Behring
Active, not recruiting --> Completed
- | carfilzomib / Generic mfg.
Clinical: Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function (clinicaltrials.gov) - Nov 11, 2013
P2, N=36, Completed, Sponsor: Onyx Therapeutics, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | cyclophosphamide / Generic mfg., carfilzomib / Generic mfg.
P1 data: CHAMPION 2: A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects (clinicaltrials.gov) - Nov 7, 2013
P1, N=27, Recruiting, Sponsor: Onyx Therapeutics, Inc.
- ||| Enrollment open: Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) (clinicaltrials.gov) - Nov 7, 2013
P1, N=64, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Mekinist (trametinib) / Novartis, BeiGene, afuresertib (LAE002) / Laekna Therap
Enrollment change, Combination therapy: A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers (clinicaltrials.gov) - Nov 6, 2013
P1/2, N=20, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting N=335 --> 20
- | Istodax (romidepsin) / Astellas, BMS
Clinical: Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma (clinicaltrials.gov) - Nov 6, 2013
P1/2, N=48, Recruiting, Sponsor: Weill Medical College of Cornell University
- | Mekinist (trametinib) / Novartis, BeiGene, afuresertib (LAE002) / Laekna Therap
Trial completion, Combination therapy: A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers (clinicaltrials.gov) - Nov 6, 2013
P1/2, N=20, Completed, Sponsor: GlaxoSmithKline
N=335 --> 20 Active, not recruiting --> Completed
- bortezomib / Generic mfg.
Trial termination: Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 4, 2013
P2, N=6, Terminated, Sponsor: University of Utah
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Slow accrual; PI left primary institution
- Farydak (panobinostat) / Secura Bio
Trial termination, Combination therapy: Panobinostat/Velcade in Multiple Myeloma (clinicaltrials.gov) - Nov 4, 2013
P1, N=12, Terminated, Sponsor: University of Arkansas
Active, not recruiting --> Terminated; Slow accrual; PI left primary institution Active, not recruiting --> Terminated; This study was terminated because the drug company stopped making the study drug
- bortezomib / Generic mfg.
Enrollment change: Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 4, 2013
P2, N=6, Terminated, Sponsor: University of Utah
Active, not recruiting --> Terminated; This study was terminated because the drug company stopped making the study drug N=10 --> 6
- Farydak (panobinostat) / Secura Bio
Enrollment change, Combination therapy: Panobinostat/Velcade in Multiple Myeloma (clinicaltrials.gov) - Nov 4, 2013
P1, N=12, Terminated, Sponsor: University of Arkansas
N=10 --> 6 N=18 --> 12
- | dexamethasone / Generic mfg., thalidomide / Generic mfg.
New P2 trial: High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP (clinicaltrials.gov) - Nov 3, 2013
P2, N=240, Recruiting, Sponsor: Shandong University
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion: Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Oct 31, 2013
P1/2, N=70, Completed, Sponsor: German CLL Study Group
N=18 --> 12 Active, not recruiting --> Completed
- Doptelet (avatrombopag) / SOBI
Enrollment change: A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501 (clinicaltrials.gov) - Oct 30, 2013
P1, N=28, Completed, Sponsor: Eisai Inc.
Active, not recruiting --> Completed N=23 --> 28
- ||| ontuxizumab (MORAb-004) / Eisai
Enrollment open: MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Oct 30, 2013
P1, N=65, Recruiting, Sponsor: Morphotek
N=23 --> 28 Not yet recruiting --> Recruiting
- Enrollment closed, Post-transplantation: Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies (clinicaltrials.gov) - Oct 30, 2013
P2, N=42, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
Trial termination: A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) (clinicaltrials.gov) - Oct 29, 2013
P3, N=24, Terminated, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Recruiting --> Terminated; Study was terminated early due to significant enrollment challenges.
- | Doptelet (avatrombopag) / SOBI
Enrollment change: Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) (clinicaltrials.gov) - Oct 29, 2013
P3, N=49, Completed, Sponsor: Eisai Inc.
Recruiting --> Terminated; Study was terminated early due to significant enrollment challenges. N=100 --> 49
- Doptelet (avatrombopag) / SOBI, Promacta (eltrombopag) / Novartis
Enrollment change: A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) (clinicaltrials.gov) - Oct 29, 2013
P3, N=24, Terminated, Sponsor: Eisai Inc.
N=100 --> 49 N=350 --> 24
- Enrollment change: A Phase II Study of Umbilical Cord Blood Transplantation (clinicaltrials.gov) - Oct 29, 2013
P2, N=7, Active, not recruiting, Sponsor: Tufts Medical Center
N=350 --> 24 N=10 --> 7
- Enrollment closed: A Phase II Study of Umbilical Cord Blood Transplantation (clinicaltrials.gov) - Oct 29, 2013
P2, N=7, Active, not recruiting, Sponsor: Tufts Medical Center
N=10 --> 7 Recruiting --> Active, not recruiting
- Mozobil (plerixafor) / Sanofi
Trial completion: Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil (clinicaltrials.gov) - Oct 29, 2013
P2, N=52, Completed, Sponsor: CancerCare Manitoba
Recruiting --> Active, not recruiting Recruiting --> Completed
- || bortezomib / Generic mfg., cyclophosphamide / Generic mfg., thalidomide / Generic mfg.
New P3 trial: Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04) (clinicaltrials.gov) - Oct 27, 2013
P3, N=340, Not yet recruiting, Sponsor: Nantes University Hospital
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial termination: High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant (clinicaltrials.gov) - Oct 24, 2013
P2, N=1, Terminated, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Completed Recruiting --> Terminated; Data was not collected, because funding was unavailable to continue study.
- Ontak (denileukin diftitox) / Eisai, TSD Japan
Trial termination: Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation (clinicaltrials.gov) - Oct 24, 2013
P1, N=2, Terminated, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Terminated; Data was not collected, because funding was unavailable to continue study. Active, not recruiting --> Terminated; Drug unavailable
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change: High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant (clinicaltrials.gov) - Oct 24, 2013
P2, N=1, Terminated, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Terminated; Drug unavailable N=22 --> 1
- Ontak (denileukin diftitox) / Eisai, TSD Japan
Enrollment change: Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation (clinicaltrials.gov) - Oct 24, 2013
P1, N=2, Terminated, Sponsor: Barbara Ann Karmanos Cancer Institute
N=22 --> 1 N=33 --> 2
- Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis
Trial completion: A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013 (clinicaltrials.gov) - Oct 24, 2013
P=N/A, N=33, Completed, Sponsor: Weill Medical College of Cornell University
N=33 --> 2 Not yet recruiting --> Completed
- Arzerra (ofatumumab) / Novartis, Genmab
Enrollment change: Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia (clinicaltrials.gov) - Oct 23, 2013
P2, N=3, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Not yet recruiting --> Completed N=28 --> 3
- Arzerra (ofatumumab) / Novartis, Genmab
Enrollment closed: Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia (clinicaltrials.gov) - Oct 23, 2013
P2, N=3, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
N=28 --> 3 Recruiting --> Active, not recruiting
- Trial termination: Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) (clinicaltrials.gov) - Oct 22, 2013
P2, N=16, Terminated, Sponsor: Marshall University
Recruiting --> Active, not recruiting Recruiting --> Terminated; Original Principal Investigator left the institution.
- Enrollment change: Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) (clinicaltrials.gov) - Oct 22, 2013
P2, N=16, Terminated, Sponsor: Marshall University
Recruiting --> Terminated; Original Principal Investigator left the institution. N=48 --> 16
- Trial termination: Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma (clinicaltrials.gov) - Oct 21, 2013
P=N/A, N=6, Terminated, Sponsor: Barbara Ann Karmanos Cancer Institute
N=48 --> 16 Suspended --> Terminated; Funding unavailable
- Enrollment change: Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma (clinicaltrials.gov) - Oct 21, 2013
P=N/A, N=6, Terminated, Sponsor: Barbara Ann Karmanos Cancer Institute
Suspended --> Terminated; Funding unavailable N=15 --> 6
- ||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed: Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT (clinicaltrials.gov) - Oct 21, 2013
P2, N=90, Active, not recruiting, Sponsor: Virginia Commonwealth University
N=15 --> 6 Recruiting --> Active, not recruiting
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial termination: Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation (clinicaltrials.gov) - Oct 21, 2013
P2, N=1, Terminated, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Active, not recruiting Suspended --> Terminated; Lack of funding.
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change: Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation (clinicaltrials.gov) - Oct 21, 2013
P2, N=1, Terminated, Sponsor: Barbara Ann Karmanos Cancer Institute
Suspended --> Terminated; Lack of funding. N=61 --> 1
- Enrollment open: Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma (clinicaltrials.gov) - Oct 21, 2013
P=N/A, N=96, Recruiting, Sponsor: Dana-Farber Cancer Institute
N=61 --> 1 Not yet recruiting --> Recruiting
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, plerixafor / Generic mfg.
Trial termination: Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide (clinicaltrials.gov) - Oct 20, 2013
P3, N=9, Terminated, Sponsor: Case Comprehensive Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; Slow Accrual
- |||| carfilzomib / Generic mfg.
Combination therapy: Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Oct 20, 2013
P2, N=55, Recruiting, Sponsor: Emory University
Active, not recruiting --> Terminated; Slow Accrual Not yet recruiting --> Recruiting
- Enrollment change: T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases (clinicaltrials.gov) - Oct 17, 2013
P2, N=13, Active, not recruiting, Sponsor: The Cleveland Clinic
Not yet recruiting --> Recruiting N=36 --> 13
- obatoclax (GX 15-070) / Teva
Trial termination, Combination therapy: Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 16, 2013
P1/2, N=11, Terminated, Sponsor: National Cancer Institute (NCI)
N=36 --> 13 Active, not recruiting --> Terminated; This trial was terminated due to slow accrual and the drug supply of Obatoclax during the phase I; therefore, the phase II portion will never open.
- obatoclax (GX 15-070) / Teva
Enrollment change, Combination therapy: Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 16, 2013
P1/2, N=11, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated; This trial was terminated due to slow accrual and the drug supply of Obatoclax during the phase I; therefore, the phase II portion will never open. N=62 --> 11
- fenofibrate / Generic mfg.
New P2 trial: Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma (clinicaltrials.gov) - Oct 16, 2013
P2, N=30, Recruiting, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
- carfilzomib / Generic mfg.
Clinical: Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease (clinicaltrials.gov) - Oct 16, 2013
P1, N=32, Recruiting, Sponsor: Onyx Therapeutics, Inc.
N=62 --> 11 Not yet recruiting --> Recruiting
- | plerixafor / Generic mfg.
Trial completion: Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant (clinicaltrials.gov) - Oct 15, 2013
P2, N=21, Completed, Sponsor: Duke University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| New P1 trial: Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) (clinicaltrials.gov) - Oct 14, 2013
P1, N=64, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- || Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
Trial initiation date: Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE (clinicaltrials.gov) - Oct 13, 2013
P=N/A, N=105, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Initiation date: Jun 2009 --> Sep 2009
- Zolinza (vorinostat) / Merck (MSD)
Enrollment open: Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (clinicaltrials.gov) - Oct 13, 2013
P2, N=12, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jun 2009 --> Sep 2009 Not yet recruiting --> Recruiting
- ||| carfilzomib / Generic mfg.
P2 data: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 10, 2013
P2, N=302, Completed, Sponsor: Onyx Therapeutics, Inc.
Not yet recruiting --> Recruiting N=250 --> 302